Buzzi Unicem (0NVQ)
London Exchange · UK · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 39.32 |
|---|---|
| 52-week range | 35.60 – 54.70 |
| Return, 1 month / 3 months | +6.9% / −4.7% |
| Return, 1 year / 3 years | −18.0% / +64.9% |
| Trend | Below its 200-day average |
| RSI (14) | 59 |
| Volatility (1 year) | 33.0% |
| Worst drawdown (1 year) | -32.2% |
| Average daily value traded | 0.96M EUR |
| Dividend yield | 1.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Buzzi Unicem is an Italian manufacturer of cement, ready-mixed concrete and natural aggregates. The company operates cement plants and concrete mixing facilities that supply construction companies, builders and infrastructure projects. Its products are used in residential, commercial and public works construction. Buzzi Unicem is based in Casale Monferrato, in northern Italy, and runs operations in several countries, with a strong presence in Italy, Germany, the United States and central Europe.
The shares are listed on the London Exchange in UK under the code 0NVQ, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Buzzi Unicem (0NVQ) trades on the London Exchange in UK. It last closed at EUR 39.32 on 23 October 2026.
Its price-based Market X-Ray is 37 out of 100 (a weak price profile), ranking 2,774 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 18.0% and over the last three months it fell 4.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 26 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -10.1% | ||
| From 52-week high | -27.7% | ||
| Momentum | 27 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -4.7% | ||
| 6-month return | -16.0% | ||
| 12-month return, skipping the last month | -23.3% | ||
| Stability (higher is calmer) | 50 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 33.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -32.2% | ||
| Liquidity | 53 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.96M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 36 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.8% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +4.2% |
|---|---|
| 1 month | +6.9% |
| 3 months | −4.7% |
| 6 months | −16.0% |
| 1 year | −18.0% |
| 3 years | +64.9% |
| 5 years | +112.7% |
Signals
| 50-day / 200-day average | 38.65 / 43.73 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.19 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 May 2026 | EUR 0.7000 |
| 19 May 2025 | EUR 0.7000 |
| 20 May 2024 | EUR 0.6000 |
| 22 May 2023 | EUR 0.4500 |
| 23 May 2022 | EUR 0.4000 |
| 24 May 2021 | EUR 0.2500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.